A preventable infection thought largely conquered is making a quiet, devastating return
A disease once considered a relic of less medically advanced eras has returned to haunt the most vulnerable — pregnant women and their unborn children — not because medicine forgot how to stop it, but because the systems meant to deliver that medicine quietly collapsed. Across the United States, syphilis infections among expectant mothers have climbed to rates unseen in decades, a direct inheritance of pandemic-era disruptions to prenatal care and antibiotic supply chains. The tragedy at the center of this story is not scientific mystery but systemic failure: a curable infection, requiring only a test and a single course of antibiotics, is now causing birth defects, stillbirths, and lifelong disability in newborns who had no say in the matter.
- Syphilis cases among pregnant women have surged to levels not seen in decades, with concentrated outbreaks mapped across multiple U.S. counties from New York to the South and beyond.
- Pandemic lockdowns shattered prenatal care routines just as Bicillin L-A — the only reliable antibiotic treatment for syphilis in pregnancy — disappeared from pharmacy shelves, leaving infected women with no path to protection.
- Newborns are now arriving with congenital syphilis, facing bone disease, blindness, deafness, stillbirth, and intellectual disability — harms that are entirely preventable with timely screening and treatment.
- Public health agencies have issued warnings and published risk maps, but the structural problems — drug shortages, uneven rural access, lagging screening rates — remain stubbornly unresolved.
- The crisis raises an uncomfortable question about what else fractured silently during the pandemic, as officials watch for further resurgences while families already bear the cost of the gaps left behind.
A preventable infection thought largely defeated in wealthy nations is making a quiet and devastating return. Syphilis cases among pregnant women have climbed sharply since the pandemic, and the consequences are falling on newborns who never had a choice in the matter.
The surge is not random. It traces back to specific failures in American healthcare during and after the pandemic years. When lockdowns took hold, prenatal care fractured — women delayed or skipped routine screenings, clinics reduced hours, and the infrastructure that once caught syphilis before it could cross the placenta simply wasn't there. Simultaneously, Bicillin L-A, the antibiotic that has been the standard cure for generations, vanished from pharmacy shelves. Women who tested positive couldn't access the medication that would protect their pregnancies.
The result is congenital syphilis — infection passed from mother to child. Newborns born with this disease face birth defects, stillbirth, and complications that can unfold over years: bone disease, blindness, deafness, intellectual disability. These are not theoretical harms. They are happening now, in hospitals across the country.
Health officials have sounded alarms and the CDC has published maps showing where risk is highest, but the underlying problems persist. Bicillin L-A shortages continue. Prenatal care access remains uneven, particularly in rural areas. Screening rates have not fully recovered.
What makes this crisis particularly bitter is its preventability. A single course of antibiotics, given early, eliminates the risk to the fetus almost entirely — no vaccine, no complex intervention, just access to a test and access to medicine. For the women carrying infected pregnancies right now, and for the children already born with a disease their mothers could have been cured of, the system's failure to maintain even that basic threshold of care has arrived too late to undo.
A preventable infection thought largely conquered in wealthy nations is making a quiet, devastating return. Syphilis cases among pregnant women have climbed sharply since the pandemic ended, and the consequences are landing directly on newborns who never had a choice in the matter.
The numbers tell a stark story. Across multiple U.S. counties—from Broome County in New York to regions tracked on CDC maps showing concentrated risk—pregnant women are testing positive for syphilis at rates not seen in decades. The surge is not random. It traces back to specific, identifiable failures in the machinery of American healthcare during and after the pandemic years.
When lockdowns took hold, prenatal care fractured. Pregnant women delayed or skipped routine screening appointments. Clinics reduced hours. The infrastructure that once caught syphilis early—before it could cross the placenta and infect a developing fetus—simply wasn't there. At the same time, treatment itself became scarce. Bicillin L-A, the antibiotic that has been the standard cure for syphilis for generations, vanished from pharmacy shelves. Supply chains broke. Manufacturing couldn't keep pace. Women who tested positive couldn't access the medication that would protect their pregnancies.
The result is congenital syphilis—infection passed from mother to child. Newborns born with this disease face a grim menu of possibilities: birth defects, stillbirth, neonatal complications that can unfold over months or years. A child born with untreated maternal syphilis may develop bone disease, blindness, deafness, or intellectual disability. These are not theoretical harms. They are happening now, in hospitals across the country.
Health officials have begun sounding alarms, but the machinery of response moves slowly. The CDC has published maps showing where risk is highest. Public health departments have issued warnings. But the underlying problems persist. Bicillin L-A shortages continue. Prenatal care access remains uneven, particularly in rural areas and among populations with the least margin for error. Screening rates have not fully recovered to pre-pandemic levels.
What makes this crisis particularly bitter is its preventability. Syphilis in pregnancy is one of the easiest infections to stop. A single course of antibiotics, given early, eliminates the risk to the fetus almost entirely. No vaccine needed. No complex intervention. Just access to a test and access to medicine. Yet thousands of pregnant women and their newborns are paying the price for a system that failed to maintain even that basic threshold of care.
The trend points toward a harder question: what else broke during the pandemic that we haven't yet noticed? What other preventable diseases are quietly resurging in the gaps left behind? Health officials are watching. But for the women carrying infected pregnancies right now, and for the children being born with a disease their mothers could have been cured of, the watching has come too late.
Citas Notables
Health officials warn that syphilis is making a comeback, with CDC maps showing concentrated risk across multiple regions— CDC and public health officials
La Conversación del Hearth Otra perspectiva de la historia
Why did syphilis cases spike specifically in pregnant women? Wasn't the pandemic hard on everyone?
It was, but pregnant women hit a particular vulnerability. They need consistent prenatal care—screening, monitoring, follow-up. When clinics closed or reduced hours, they fell through the cracks. And if they tested positive, they couldn't get treated.
Because of the Bicillin shortage?
Exactly. Bicillin L-A is the standard treatment. It's been the standard for decades. When supply chains broke during the pandemic, there was no backup plan, no alternative that worked as well. Women who needed it couldn't get it.
So this is a supply chain story, not a disease story?
It's both. The disease itself never went away—it was always circulating. But the systems that catch and treat it broke. Reduced prenatal screening, disrupted access to medication. The pandemic exposed how fragile those systems are.
What happens to a baby born with congenital syphilis?
It depends on severity and how early it's caught after birth. Birth defects, bone disease, blindness, deafness. Some children develop complications months or years later. All of it preventable if the mother had been treated during pregnancy.
Is the shortage fixed now?
Not entirely. Supply has improved, but it's still not back to normal. And prenatal care access remains uneven, especially in rural areas. The infrastructure hasn't fully recovered.
So we're still in the middle of this crisis?
We are. Health officials are tracking it, but the underlying problems—access, screening, treatment availability—haven't been solved. The surge is ongoing.